Printer Friendly

DELAWARE VALLEY'S ENTREPRENEUR OF THE YEAR AWARD SELECTS PHILIP S. SCHEIN, M.D.

 DELAWARE VALLEY'S ENTREPRENEUR OF THE YEAR AWARD
 SELECTS PHILIP S. SCHEIN, M.D.
 WEST CONSHOHOCKEN, Pa., June 29 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS) is proud to announce that its chairman and chief executive officer, Philip S. Schein, M.D., is the recipient of the Delaware Valley's Entrepreneur of the Year Award in the "Emerging Company" category.
 As the founder of the U.S. Bioscience five years ago, the award recognizes Dr. Schien's scientific and management contributions to the establishment of a highly successful company dedicated to improving the quality of life and care for cancer patients.
 In accepting the award, Dr. Schein said: "The creation of U.S. Bioscience has provided an opportunity to make an important impact on the treatment of cancer patients on a worldwide basis."
 The Entrepreneur of the Year competition seeks to identify superior performances among entrepreneurial companies. Thirty finalists were selected in eight categories among companies scattered throughout the Delaware Valley.
 Prior to joining U.S. Bioscience, Dr. Schein was vice president of Worldwide Clinical Research and Development, Smith Kline & French Laboratories. Earlier, he served as scientific director of the Vincent T. Lombardi Cancer Research Center at the Georgetown University School of Medicine in Washington. He also served as senior investigator and head of the clinical pharmacology section of the medicine branch, National Cancer Institute, Bethseda, Md.
 Dr. Schein has authored over 350 articles and texts relating to basic and clinical cancer research and drug development. He served as president of the American Society of Clinical Oncology and he has chaired the Food and Drug Administration's Oncology Drugs Advisory Committee, where he received the commissioner's Special Citation and the Harvey W. Wiley Medal.
 U.S. Bioscience's portfolio includes a broad spectrum of drugs for cancer and AIDS, including four products in the late stages of development. One compound, altretamine, is marketed under the name Hexalen in the United States for patients with advanced, refractory cancer of the ovary.
 /delval/
 -0- 6/29/92
 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503/ CO: U.S. Bioscience ST: Pennsylvania IN: MTC SU: PER


RM -- SJ003 -- 4714 06/29/92 12:21 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1992
Words:358
Previous Article:MAGNETECH EXTENDS WARRANT EXERCISE DATE ADDITIONAL 31 DAYS
Next Article:DELL CUTS PRICES, EXPANDS SERVICES AND SUPPORT AND ADDS NEW LOW-COST LINE OF PCs; CAPITALIZES ON OPERATING EFFICIENCIES TO OFFER MORE VALUE
Topics:


Related Articles
U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST
U.S. BIOSCIENCE DISCLOSES ALLEGED CLASS ACTION SUIT
U.S. BIOSCIENCE OBTAINS RIGHTS TO SELL OVARIAN CANCER DRUG IN EUROPE AND ISRAEL
U.S. BIOSCIENCE REPORTS SECOND QUARTER RESULTS OF OPERATIONS
U.S. BIOSCIENCE REPORTS RESULTS FOR FOURTH QUARTER AND YEAR
U.S. BIOSCIENCE NAMES MARTHA MANNING VICE PRESIDENT, GENERAL COUNSEL
MACMASTER, FORMER MERCK EXECUTIVE, NAMED TO U.S. BIOSCIENCE BOARD
ENTREPRENEUR OF THE YEAR AWARDS FINALISTS ANNOUNCED
Vion Appoints Alan Kessman CEO; Company Also Strengthens Clinical Team, Naming Philip Schein Senior Advisor for Medical and Regulatory Operations.
'The Oncologist' Journal Reports FDA's Role in New Cancer Drugs.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters